Status:
RECRUITING
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
Lead Sponsor:
Fondazione Italiana Linfomi - ETS
Conditions:
Follicular Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective biological study evaluating the persistence of COVID-19 vaccine and other vaccines' (zoster, diphtheria and tetanus)-induced immunity in a subgroup patient affected by Follicular...
Detailed Description
Patients (pts) with follicular lymphoma (FL) were reported to be at high risk for hospitalization and death from COVID-19 infection, especially if exposed to anti-CD20 monoclonal antibodies (mAbs)-bas...
Eligibility Criteria
Inclusion
- Enrolment in FIL\_FOLL19 study
- Previous vaccination for COVID-19 (at least 3 doses)
- Availability of informations about COVID-19 and other vaccines previously administered (vaccination records)
- Willingness to comply with blood collection timepoints required for vaccination immunity evaluation
- Signature of specific informed consent form
Exclusion
- None
Key Trial Info
Start Date :
May 7 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT06070961
Start Date
May 7 2024
End Date
May 1 2027
Last Update
June 29 2025
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico
Avellino, AV, Italy, 83100
2
A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia
Alessandria, IT, Italy
3
Nuovo Ospedale degli Infermi, SSD Ematologia
Biella, IT, Italy
4
ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia
Milan, IT, Italy